-

Lassen Therapeutics to Present at the 5th Annual Idiopathic Pulmonary Fibrosis (IPF) Summit

SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a biotech company developing innovative therapeutic antibodies as potential treatments for fibrosis, rare diseases and oncology, today announced that Jamie Swaney, Ph.D., Vice President of Fibrosis & Translational Biology, is presenting at the 5th Annual IPF Summit on Friday, August 27, 2021. The title of his presentation is “Antibody Mediated Blockade of Interleukin-11 Signaling for IPF and Other Fibrosing Lung Diseases”. Dr. Swaney will describe the upregulation of IL-11 in lung fibrosis and the development and characterization of anti-IL-11 receptor antibodies to treat lung fibrosis.

About Lassen Therapeutics

Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than and additive to other anti-fibrotic therapeutic approaches. IL-11 is also an important effector of tumor microenvironment organization, playing a key role as a mediator between cancer and stromal cells. For more information, please visit www.lassentherapeutics.com

Contacts

Media Contact:
Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497

Industry:

Lassen Therapeutics

Release Versions
English

Contacts

Media Contact:
Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497

More News From Lassen Therapeutics

Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease

SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics, LASN01, targeting interleukin-11 receptor (IL-11R) as a potential treatment for fibro-inflammatory diseases such as TED and IPF, and a highly potent, first-in-class monoclonal antibody, LASN500, targeting the interleukin-18 binding protein (IL-18BP) as a potential treatment for cancer, today announced the closing of an oversubscribed Series B financing which raised...

Lassen Therapeutics Presents Preclinical Data on LASN01, an Anti-IL-11 Receptor Antibody in Development for Treatment of Thyroid Eye Disease at the American Thyroid Association 2023 Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotechnology company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R; LASN01) as a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF), and interleukin-18 binding protein (IL-18BP; LASN500), as a potential treatment for cancer, presented new preclinical data on LASN01, for treatment of TED, at the American Thyroi...

Lassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease at the European Respiratory Society (ERS) and European Thyroid Association (ETA) Annual Meetings

SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R, LASN01) as a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF), and interleukin-18 binding protein (IL-18BP, LASN500) as a potential treatment for cancer, today announced new clinical and preclinical data generated with LASN01 at the 2023 European...
Back to Newsroom